Merck & Co., Inc. $MRK Stock Bought by Focus Advisor Solutions LLC

Focus Advisor Solutions LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 49.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 128,466 shares of the company’s stock after acquiring an additional 42,377 shares during the period. Focus Advisor Solutions LLC’s holdings in Merck & Co., Inc. were worth $18,668,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of MRK. Fisher Asset Management LLC lifted its position in shares of Merck & Co., Inc. by 8.3% during the third quarter. Fisher Asset Management LLC now owns 41,699,432 shares of the company’s stock worth $6,059,345,000 after purchasing an additional 3,183,169 shares during the last quarter. Bank of America Corp DE grew its stake in Merck & Co., Inc. by 10.5% in the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Merck & Co., Inc. by 263.7% in the second quarter. Assenagon Asset Management S.A. now owns 2,702,992 shares of the company’s stock worth $347,334,000 after purchasing an additional 1,959,778 shares in the last quarter. Wellington Management Group LLP increased its holdings in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after buying an additional 1,934,312 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Merck & Co., Inc. in the third quarter valued at about $260,560,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Merck & Co., Inc.

In related news, EVP Richard Deluca sold 58,185 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the transaction, the executive vice president owned 112,955 shares in the company, valued at $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Stock Down 3.9%

MRK stock opened at $137.75 on Thursday. The stock has a market cap of $339.59 billion, a PE ratio of 45.95, a price-to-earnings-growth ratio of 6.57 and a beta of 0.13. The firm’s 50-day simple moving average is $145.73 and its 200 day simple moving average is $129.11. Merck & Co., Inc. has a fifty-two week low of $93.90 and a fifty-two week high of $156.92. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The firm had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. During the same period in the previous year, the business posted $2.58 EPS. Merck & Co., Inc.’s revenue was up 4.7% on a year-over-year basis. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.82 EPS for the current year.

Merck & Co., Inc. Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Stockholders of record on Tuesday, December 15th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 2.6%. This is an increase from Merck & Co., Inc.’s previous quarterly dividend of $0.85. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 350.52%.

Key Stories Impacting Merck & Co., Inc.

Here are a few of the latest stories about MRK:

  • Positive Sentiment: Merck raised its quarterly dividend 3.5%, from $0.85 to $0.88 per share, equivalent to $3.52 annually. The increase may appeal to income-focused investors. Merck Announces First-Quarter 2027 Dividend
  • Positive Sentiment: A roundup of recent pipeline developments cited positive European regulatory opinions for expanded ENFLONSIA and WELIREG uses, plus Phase 2b data for liver-disease candidate efinopegdutide. These programs could help broaden growth beyond KEYTRUDA, though they remain at different stages of development and review. How Investors May Respond To Merck (MRK) Pipeline Progress
  • Negative Sentiment: Merck is ending development of nemtabrutinib and stopping its BELLWAVE clinical program after safety concerns in a Phase 3 risk assessment. Losing a candidate for blood cancers removes a potential pipeline opportunity, although the company said it would focus on other assets. Merck Stops Trials of Blood Cancer Drug After Risk Assessment

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MRK shares. Berenberg Bank upped their price objective on Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a research note on Friday, September 11th. Citigroup lifted their target price on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research report on Monday, October 12th. Zacks Research downgraded Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Monday, October 19th. UBS Group upped their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Finally, Scotiabank raised their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, September 29th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $155.74.

Read Our Latest Analysis on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Read More

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.